Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients
Table 1
Patient characteristics at the time of the coronary event.
Characteristics
HIV-infected patients ()
Age, years (median [IQR])
48 (40, 57)
Patients > 50 years (%)
38.3
Gender (male) (%)
86.1
Body mass index >25 (%)
9.8
Men who have sex with men (%)
38.6
HCV coinfection (%)
4.9
HBV coinfection (%)
12.3
HIV-related characteristics
Time since diagnosis of HIV-infection, years (median [IQR])
14.9 (10.4, 19.2)
Cumulative exposure to antiretrovirals (median [IQR])
12.7 (9.3, 16.2)
Cumulative exposure to PIs (median [IQR])
5 (0.7, 8)
Cumulative exposure to NNRTIs (median [IQR])
3 (0.1, 7)
Cumulative exposure to abacavir (median [IQR])
2 (0, 11)
CD4 cells count/µL (median [IQR])
224 (89, 422)
HIV-RNA ≤ 400 copies/mL (median [IQR])
46 (56.8%)
Lipodystrophy (including lipoatrophy) (%)
36.1
Cardiovascular risk factors
Family history of coronary heart disease (%)
17 (20.5%)
Smoking (%)
36 (44%)
Cumulative exposure to tobacco smoke, years (mean [SD])
23 (9.4)
Hypertension (%)
49 (60.5)
*Use of antihypertensive treatment (%)
43 (87.8)
Diabetes mellitus (%)
13 (16)
*Use of antidiabetic treatment (%)
10 (76.9)
Dyslipidemia (%)
44 (48.1)
Serum total cholesterol, mg/dL (median [IQR])
182 (152, 230)
Serum HDL-cholesterol, mg/dL (median [IQR])
42 (35, 52)
Serum LDL-cholesterol, mg/dL (median, [IQR])
104 (98, 194)
Serum triglycerides, mg/dL (median, [IQR])
168 (106, 248)
*Use of lipid-lowering agents (%)
39 (88.6)
Data was reported as median and interquartile range [IQR].
*Percentages of patients using antihypertensive drugs, antidiabetic treatment or lipid-lowering agents were calculated considering the number of patients receiving that treatment with respect to those who required treatment (considering target parameters according to the guidelines).
